跳至主要内容
临床试验/NCT06859892
NCT06859892招募中4 期

Effect of Dexmedetomidine-esketamine Combination on Sleep Disturbances After Major Noncardiac Surgery: a Single-center, Randomised, Double-blind, Placebo-controlled Trial

Peking University First Hospital1 个研究点 分布在 1 个国家目标入组 476 人开始时间: 2025年3月18日最近更新:
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
入组人数
476
试验地点
1
主要终点
Incidence of sleep disturbances within 3 days after surgery

研究概览

简要总结

Sleep disturbances are common early after major surgery, and are associated with delayed recovery. A previous study showed that dexmedetomidine-esketamine combination as a supplement to patient-controlled intravenous analgesia improved postoperative analgesia and subjective sleep quality in patients after scoliosis correction surgery. The purpose of this trial is to test the hypothesis that dexmedetomidine-esketamine combination used as a supplement during general anesthesia and postoperative intravenous analgesia may reduce sleep disturbances in adult after major noncardiac surgery.

详细描述

Sleep disturbances after surgery is usually manifested as sleep deprivation, altered circadian rhythm, and disturbed sleep structure. The reported incidence of sleep disturbances was 31.4% after gynecologic surgery, 31.9% after urologic surgery, and 35.9% after spine surgery. The occurrence of sleep disturbances is associated with worse perioperative outcomes, including aggravated pain intensity, increased delirium, higher risk of cardiovascular events, and delayed hospital discharge.

Dexmedetomidine is a high-specific alpha 2-adrenergic agonist with anxiolytic, sedative, and analgesic effects. When used during general anesthesia and for postoperative analgesia, dexmedetomidine is associated with improved analgesia and sleep quality. The effect of dexmedetomidine is dose-dependent. However, even commonly used dosage increases bradycardia and hypotension.

Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. Esketamine is the S-enantiomer of racemic ketamine with a higher affinity for NMDA receptors and is approximately twice as potent as racemic ketamine in analgesia. When used during general anesthesia and for postoperative analgesia, esketamine improves analgesia and reduces opioid consumption, but psychiatric symptoms may occur.

The sedative effect of dexmedetomidine is helpful to relieve psychiatric side effects of ketamine/esketamine. A previous study showed that dexmedetomidine-esketamine combination as a supplement to patient-controlled intravenous analgesia improved postoperative analgesia and subjective sleep quality in patients after scoliosis correction surgery.

This trial is designed to test the hypothesis that dexmedetomidine-esketamine combination used as a supplement during general anesthesia and postoperative intravenous analgesia may reduce sleep disturbances in adult after major noncardiac surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged ≥18 years.
  • Scheduled for major noncardiac surgery (≥60 minutes) under general anesthesia with an expected end of surgery no later than 18:00 pm.
  • Required patient-controlled intravenous analgesia after surgery.

排除标准

  • Emergency surgery, transurethral surgery, organ transplantation.
  • Pregnant or lactating women.
  • Patients who need hypnotics for sleep disturbance or antidepressants for depression prior to surgery.
  • History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis.
  • Inability to communicate due to coma, severe dementia, or speech disorders, endured hypoxic encephalopathy or traumatic brain injury, or after neurosurgery.
  • Comorbid with hyperthyroidism and pheochromocytoma.
  • Preoperative left ventricular ejection fraction <30%, sick sinus syndrome, severe sinus bradycardia (heart rate <50 beats/min), atrioventricular block of degree II or higher without pacemaker implantation, or systolic blood pressure below 90 mmHg despite use of vasopressors.
  • Diagnosed as sleep apnea, or judged to be at high risk of moderate-to-severe sleep apnea as assessed by STOP-Bang.
  • Severe hepatic dysfunction (Child-Pugh class C), severe renal dysfunction (on dialysis), or ASA classification ≥IV.
  • Hypersensitive to dexmedetomidine and/or esketamine.
  • Other conditions that are deemed unsuitable for study participation.

研究组 & 干预措施

Dexmedetomidine-esketamine group

Experimental

Dexmedetomidine-esketamine combination is infused during general anesthesia and used as a supplement for patient-controlled intravenous analgesia after surgery.

干预措施: Dexmedetomidine-esketamine combination (Drug)

Placebo group

Placebo Comparator

Placebo (normal saline) is infused during general anesthesia and used as a supplement for patient-controlled intravenous analgesia after surgery.

干预措施: Placebo (Drug)

结局指标

主要结局

Incidence of sleep disturbances within 3 days after surgery

时间窗: Up to 3 days after surgery

Sleep disturbances are defined as Richards-Campbell Sleep Questionnaire (RCSQ) score below 50, based on assessments conducted daily between 8:00 am and 10:00 am during postoperative days 1 to 3.

次要结局

  • Quality of recovery at 24 hours after surgery(At 24 hours after surgery)
  • Subjective sleep quality in the first 3 nights after surgery.(Up to 3 days after surgery.)
  • Pain intensity both at rest and with movement during the first 3 postoperative days(Up to 3 days after surgery)
  • Anxiety and depression on the third day after surgery(On the third day after surgery)
  • Subjective sleep quality on the 30th day after surgery(On the 30th day after surgery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mo Li

Anesthesiologist, Department of Anesthesiology

Peking University First Hospital

研究点 (1)

Loading locations...

相似试验